Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.allogene.com
Allogene Therapeutics News Releases
Get the latest updates from Allogene Therapeutics News Releases directly as they happen.
Follow now 88 followers
Latest posts
Last updated 3 days ago
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
3 days ago
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m...
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
16 days ago
SOUTH SAN FRANCISCO, Calif. , April 23, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
about 1 month ago
Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION...
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
about 2 months ago
Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene...
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
2 months ago
Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m...
Allogene Therapeutics Announces Participation in March Investor Conference
2 months ago
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
2 months ago
SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
3 months ago
Efficacy Comparable to Approved Autologous CD19 CAR Ts: Achieved Overall Response (ORR)...
Allogene Therapeutics Announces Participation in February Investor Conferences
3 months ago
SOUTH SAN FRANCISCO, Calif. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
3 months ago
SOUTH SAN FRANCISCO, Calif. , Jan. 29, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
3 months ago
Dual-Targeted CD19/CD70 Allogeneic CAR T: Best-in-Class Design to Enhance Therapeutic Benefit and...
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
5 months ago
SOUTH SAN FRANCISCO, Calif. , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene...